Ventripoint Diagnostics Ltd. — Capital/Financing Update 2021

Feb 9, 2021

==> picture [197 x 52] intentionally omitted <==

Ventripoint Issues Option Grants

Toronto, Ontario, February 8, 2021 – Ventripoint Diagnostics Ltd. (“ Ventripoint ” or the “ Corporation ”, TSXV:VPT & OTC:VPTDF) announces that on February 5, 2021 the Board of Directors approved the granting of 900,000 options to consultants at an exercise price of $0.25 for a term of 2-5 years and vesting from immediately to 1 year. The Corporation now has 135,000 options available for future grants under the Stock Option Plan as approved by shareholders at the last Special and Annual General Meeting on December 14, 2020.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

For further information, please contact:

Dr. George Adams Email: gadams@ventripoint.com Tel : 519-803-6937

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.